AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$UTHR

ROTHBLATT MARTINE A sold $5.2M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $544.94 ($531.92–$550.72, $5.18M total) across 17 trades on 2026-10-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 13, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
high confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The $5.2M sale reduces the CEO's ownership and may be interpreted as a lack of confidence, potentially prompting short‑term selling pressure.

02

Market read

Insider sell of this size is material for UTHR and could affect short‑term price dynamics.

03

What to watch

Rothblatt's 10b5‑1 plan may be used for tax or diversification purposes, not necessarily indicating outlook change.

Relevance 5/10Novelty 6/10Timing: post‑market today

Background

Form 4 filings provide the first public disclosure of insider transactions. United Therapeutics (NASDAQ: UTHR) is a mid‑cap biotech focused on pulmonary and cardiovascular therapies.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

CEO Martine Rothblatt sold $5.2M of United Therapeutics shares via a 10b5-1 plan, reducing her stake to 324,443 shares.

Expected impact

likely modest downside as the market prices in the insider sell

Evidence & confidence

A $5.2M sale by the chairperson/CEO is material for a mid‑cap biotech and is disclosed for the first time via Form 4.

Market effects

Sector

May raise concerns for the biotech sector about insider sentiment but limited broader impact.

Regional

Primarily U.S. market; no notable regional effect.

Global

Low; relevance confined to United Therapeutics investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics, insider seller

  • company
    United Therapeutics Corp

    Biopharma company listed on NASDAQ under ticker UTHR

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min